News >

ODAC Unanimously Supports Approval of First Biosimilar

Jason M. Broderick @jasoncology
Published: Wednesday, Jan 07, 2015

Dr. Deborah Armstrong

Deborah Armstrong, MD

In a 14-0 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of EP2006, a biosimilar version of filgrastim (Neupogen; Amgen). If the FDA follows the recommendation, the drug would become the first biosimilar approved in the United States.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication
x